Reactivation of Epstein–Barr virus in Aplastic Anemia: A clinical challenge

Yıl 2020, Cilt: 37 Sayı: 4, 143 - 147, 11.09.2020

Nilesh Wasekar Girish Badarkhe Samadhan Pawar Chaitanya Borde Yasam Venkata Ramesh Raj Nagarkar

Öz

Background: Acquired aplastic anemia is an unusual disease associated with pancytopenia characterized by hypocellular bone marrow. Aplastic anemia is an auto-immune disorder wherein patients would show a antithymocyte globulin (ATG)- induced hematological response after T-cell reduction. The combination of cyclosporine A and ATG as immunosuppressive therapy is considered as the standard treatment approach for patients with aplastic anemia. EBV infection in a patient with aplastic anemia is an unusual clinical presentation.
Case Report: A 49-year-old Asian female presented to our hospital with dizziness and fatigue. The patient’s platelet count was extremely low. A hypocellular marrow with lymphocytosis was observed with the help of a bone marrow aspirate and biopsy. The patient was given cyclosporine and eltrombopag as a bridge to primary therapy, i.e. antithymocyte globulin (ATG)/allogenic transplant considering she had pancytopenia. The patient developed platelet refractoriness. Epstein-Barr virus polymerase chain reaction (PCR) was performed, considering the patient’s atypical presentation. As per the results, it was significantly positive with 2250 copies/ul. A diagnosis of aplastic anemia with EBV infection was made.

Anahtar Kelimeler

Aplastic anemia, Immunosuppression, Epstein-Barr virus infections

Kaynakça

• 1. Young N. S., Calado R. T., Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–2519.
• 2. Takahashi T, Maruyama Y, Saitoh M, Itoh H, Yoshimoto M, Tsujisaki M. Fatal Epstein-Barr Virus Reactivation in an Acquired Aplastic Anemia Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine A. Case Rep Hematol. 2015;2015:926874.
• 3. Stanfield BA, Luftig MA. Recent advances in understanding Epstein-Barr virus. F1000Res. 2017;6:386.
• 4. Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015;47(1):e132.
• 5. van Esser J. W. J., van der Holt B., Meijer E., et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98(4):972–978.
• 6. Scheinberg P., Fischer S. H., Li L., et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109(8):3219–3224.
• 7. Patel KR, Bertuch A, Sasa GS, Himes RW, Wu H. Features of hepatitis in hepatitis-associated aplastic anemia: Clinical and histopathologic study J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):e7-e12.
• 8. Khurana A Dasanu CA. Hepatitis associated aplastic anemia: case report and discussion. Conn Med. 2014 Sep;78(8):493-5.
• 9. Ishimura M, Ohga S, Ichiyama M, Kusuhara K, Takada H, Hara T et al. Hepatitis-associated aplastic anemia during a primary infection of genotype 1a torque teno virus. European Journal of Pediatrics. 2010 Jul 1;169(7):899-902.
• 10. Schenke C, Alejandre-Alcázar MA, Holter W, Korn K, Papadopoulos T, Köhler H. Aplastic anemia following hepatitis associated with human herpesvirus 6. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):527-9.
• 11. Mashima K, Yano S, Yokoyama H, et al. Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature Review. Intern Med. 2017;56(6):701–706.
• 12. Zhang T, Liu C, Liu H, Li L, Wang T, Fu R. Epstein Barr Virus Infection Affects Function of Cytotoxic T Lymphocytes in Patients with Severe Aplastic Anemia. Biomed Res Int. 2018;2018:6413815.
• 13. Lazarus KH, Baehner RL. Aplastic anemia complicating infectious mononucleosis: a case report and review of the literature. Pediatrics. 1981;67:907–910.
• 14. Anderlini P, Riggs SA, Korbling M, Champlin R. Syngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia. Br J Haematol 1999;106(1):159–161.
• 15. Purtilo DT, Sakamoto K, Barnabei V. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. Am J Med, 1982;73:49–56.
• 16. Cabot RC, Scully RE, Mark EJ, McNeely BU. Case records of the Massachusetts General Hospital. Case 31-1984. N Engl J Med 1984; 311:314–322.
• 17. Grishaber JE, McClain KL, Mahoney DH Jr, Fernbach DJ. Successful outcome of severe aplastic anemia following Epstein-Barr virus infection. Am J Hematol 1988;28:273–275.
• 18. Shadduck RK, Winkelstein A, Zeigler Z, et al. Aplastic anemia following infectious mononucleosis: possible immune etiology. Exp Hematol 1979;7:264–271.
• 19. Ahronheim GA, Auger F, Joncas JH, Ghibu F, Rivard G-E, Rab-Traub N. Primary infection by Epstein-Barr virus presenting as aplastic anemia. N Engl J Med 1983;309:313–314.
• 20. Swerdlow S. H., Webber S. A., Chadburn A., Ferry J. A. Post-transplant lymphoproliferative disorders. In: Swerdlow S. H., Campo E., Harris N. L., et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. pp. 343–349.